4//SEC Filing
MATLIN DAVID J 4
Accession 0001415889-25-003623
CIK 0001826667other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 6:04 PM ET
Size
6.9 KB
Accession
0001415889-25-003623
Insider Transaction Report
Form 4
MATLIN DAVID J
Director
Transactions
- Other
Series A Preferred Stock
2025-02-10+89,501→ 189,501 totalExercise: $5.28→ Common Stock (89,501 underlying)
Footnotes (5)
- [F1]The conversion price (the "Conversion Price") reflects the reset effective as of February 10, 2025, which reset occurred in accordance with the terms of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer filed with the Delaware Secretary of State on August 10, 2023.
- [F2]Effective February 10, 2025, the Conversion Price of the 100,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock.
- [F3]After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 189,501 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election.
- [F4]All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.
- [F5]Represents the incremental number of shares of Common Stock that are issuable upon conversion of the Preferred Stock as a result of the Conversion Price reset.
Documents
Issuer
TriSalus Life Sciences, Inc.
CIK 0001826667
Entity typeother
Related Parties
1- filerCIK 0001251956
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 6:04 PM ET
- Size
- 6.9 KB